Last updated: January 25, 2026
Executive Summary
YUPELRI (reverfenacin), a nebulized long-acting muscarinic antagonist (LAMA), is FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD). Since its approval in 2018, market dynamics, ongoing clinical trials, and competitive positioning have evolved significantly. This report provides an updated analysis of ongoing clinical trials, comprehensive market landscape, and future growth projections. It aims to guide stakeholders, including pharmaceutical companies, investors, and healthcare providers, in understanding YUPELRI's current status and future potential.
Clinical Trials Update
Active and Recently Completed Trials
| Trial ID |
Title |
Status |
Purpose |
Enrollment |
Key Dates |
Sponsor |
| NCT number |
Efficacy & Safety Study of YUPELRI in COPD |
Completed |
Evaluate long-term safety, tolerability, and efficacy |
300 |
2016–2021 |
Theravance Biopharma / Mylan |
| NCT04978954 |
YUPELRI vs. Tiotropium in COPD |
Recruiting |
Head-to-head comparison; assess efficacy, safety, respiratory function |
420 |
Expected completion: 2024 |
Theravance Biopharma / Mylan |
| NCT05128994 |
YUPELRI in Elderly Patients with COPD |
Ongoing |
Assess safety, tolerability, and effectiveness in elderly |
150 |
Data anticipated 2024 |
Theravance Biopharma |
Upcoming Trials
- Long-term Safety Study in COPD (NCT05578958): Expected to enroll 500 patients, targeting completion in late 2024, focusing on cardiovascular and respiratory safety over 2 years.
- Combination Therapy Trials: Investigate YUPELRI with inhaled corticosteroids (ICS) and LABAs, with recruitment anticipated in 2023–2024, aiming to establish broader COPD management protocols.
Key Takeaways
- Evidence suggests favorable long-term safety and efficacy profiles.
- Comparative studies vs. existing LAMAs like tiotropium are underway.
- A focus on geriatric populations and combination therapies is emerging.
Market Analysis
Current Market Landscape
| Parameter |
Data |
Source/Notes |
| Global COPD Drug Market (2022) |
USD 13.1 billion |
Statista |
| YUPELRI Market Share (2022) |
Approx. 4% in inhaled COPD segment |
IQVIA |
| Number of COPD Patients (Global, 2022) |
Over 250 million; rising globally |
WHO |
| Key Competitors |
Spiriva (tiotropium), Seebri (glycopyrronium), Incruse (umeclidinium) |
Market Reports (IQVIA, EvaluatePharma) |
Market Segments
| Segment |
Description |
Market Size (USD) |
Key Players |
Notes |
| Nebulized COPD Medications |
YUPELRI, Combivent, others |
USD 2.1 billion |
Theravance, Boehringer Ingelheim |
YUPELRI holds ~4% share (2022) |
| Dry-Powder Inhalers |
Spiriva, Incruse |
USD 9 billion |
Boehringer, GSK |
Dominates inhaler market; YUPELRI as alternative |
Growth Drivers
- Increasing COPD prevalence, especially among aging populations.
- Growing preference for nebulized formulations among elderly or severe COPD patients.
- Extending indications to other obstructive lung diseases.
Market Constraints
- Intense competition from established inhalers.
- Regulatory hurdles in expanding indications.
- Limited awareness compared to inhalation devices.
Regional Perspectives
| Region |
Market Share |
Growth Rate (2022-2027) |
Factors |
| North America |
55% |
4.5% |
High COPD prevalence, insurance coverage |
| Europe |
30% |
4.2% |
Similar healthcare infrastructure |
| Asia-Pacific |
10% |
6% |
Rapid COPD growth, expanding healthcare access |
| Rest of World |
5% |
3.8% |
Limited access and infrastructure |
Market Projection (2023–2028)
| Year |
Estimated Market Size |
Compound Annual Growth Rate (CAGR) |
Notes |
| 2023 |
USD 2.2 billion |
4.2% |
Continued growth, new clinical data |
| 2024 |
USD 2.3 billion |
|
Expansion in emerging markets |
| 2025 |
USD 2.4 billion |
|
Increased adoption due to competition |
| 2026 |
USD 2.5 billion |
|
Entry of combination formulations |
| 2027 |
USD 2.7 billion |
|
Payer coverage expansion |
| 2028 |
USD 2.9 billion |
|
Anticipation of new indications |
Drivers of Growth
- Aging populations worldwide.
- Increasing COPD diagnosis rates.
- Development of fixed-dose combination inhalers including YUPELRI.
- Payer and formulary acceptance in major markets.
Risks and Challenges
- Competition from generic LAMAs and new therapeutics.
- Market saturation in mature regions.
- Regulatory delays affecting label expansions.
Comparison with Competitors
| Attribute |
YUPELRI |
Spiriva |
Seebri |
Incruse |
| Formulation |
Nebulizer |
Inhaler (capsule) |
Inhaler (capsule) |
Inhaler (Ellipta) |
| Dosage Frequency |
Once daily |
Once daily |
Once daily |
Once daily |
| Onset of Action |
15 min |
15 min |
15 min |
15 min |
| Side Effect Profile |
Similar to other LAMAs |
Similar |
Similar |
Similar |
| Approved Indications |
COPD |
COPD |
COPD |
COPD |
| Approved Year |
2018 |
2004 |
2013 |
2014 |
Regulatory and Policy Landscape
- FDA approval based on pivotal phase III trial (NCT02595894) demonstrating non-inferiority to tiotropium.
- As per the 2022 update, YUPELRI qualifies for inclusion in COPD treatment guidelines by professional societies.
- Pending discussions on label expansion for indications such as asthma or bronchiectasis.
- Reimbursement policies favor nebulized formulations in certain elderly and severe COPD populations.
Future Outlook and Strategic Opportunities
Potential for Expanded Indications
- Exploring use in asthma maintenance therapy.
- Investigating efficacy in bronchiectasis and other obstructive pulmonary diseases.
Innovations in Formulation and Delivery
- Development of combination fixed-dose products with ICS or LABAs.
- Integration with smart inhaler technology for adherence monitoring.
- Enabling portable nebulization systems for home use.
Partnerships and Collaborations
- Collaborate with healthcare providers for targeted education.
- Partner with insurance payers for formulary inclusion.
- Invest in clinical studies to support label expansions.
Key Takeaways
- Clinical Stability: YUPELRI has demonstrated a strong safety and efficacy profile in COPD, with ongoing trials focusing on long-term outcomes and comparative effectiveness.
- Market Position: Currently a niche within a broad COPD landscape, YUPELRI’s unique nebulized formulation offers advantages in specific patient populations but faces stiff competition from inhaler-based therapies.
- Growth Potential: Market projections indicate steady growth driven by demographic trends, clinical adoption, and potential label expansions.
- Strategic Focus: Emphasize combination therapies, geographic expansion, and targeted marketing toward elderly and severe COPD patients.
- Competitive Edge: Ongoing head-to-head trials and strategic partnerships will be crucial for increasing market share.
FAQs
Q1: What are the main clinical advantages of YUPELRI over inhaler-based therapies?
A1: YUPELRI offers a nebulized solution that simplifies medication administration for elderly and severely disabled COPD patients who struggle with inhaler techniques, supporting adherence and consistent drug delivery.
Q2: How does YUPELRI compare to other LAMAs in efficacy and safety?
A2: Clinical trials indicate non-inferior efficacy compared to tiotropium, with a comparable safety profile. Head-to-head studies are ongoing to further clarify comparative benefits.
Q3: What are the challenges in expanding YUPELRI’s market presence?
A3: Key challenges include intense competition from established inhaler therapies, regulatory hurdles for new indications, and limited awareness in primary care settings.
Q4: Are there any upcoming clinical trials that could influence YUPELRI’s positioning?
A4: Yes, studies assessing long-term safety, elderly patient populations, and combination therapy efficacy are underway, which may support label expansions and broader clinical use.
Q5: What strategic actions should stakeholders consider to capitalize on YUPELRI’s market?
A5: Stakeholders should prioritize clinical validation, forge strategic partnerships for distribution and reimbursement, and focus on market segments that benefit most from nebulized therapy options.
References
[1] Theravance Biopharma. (2022). YUPELRI (Revefenacin) Prescribing Information.
[2] IQVIA. (2022). Global COPD Market Reports.
[3] World Health Organization. (2022). COPD Data and Statistics.
[4] ClinicalTrials.gov. (2023). Search for YUPELRI and related studies.
[5] EvaluatePharma. (2022). COPD Therapeutics Market Outlook.
